Categories
Health

Pfizer and Moderna Vaccines Prone to Produce Lasting Immunity, Research Finds

The vaccines from Pfizer-BioNTech and Moderna trigger a sustained immune response in the body that can protect against the coronavirus for years, scientists reported on Monday.

The results add to the growing evidence that most people immunized with the mRNA vaccines may not need a booster dose as long as the virus and its variants do not progress much beyond their current forms – which is not guaranteed. People who have recovered from Covid-19 before they were vaccinated may not need a booster vaccination, even if the virus goes through a significant transformation.

“It’s a good sign of how persistent our immunity to this vaccine is,” said Ali Ellebedy, an immunologist at Washington University in St. Louis who led the study, which was published in the journal Nature.

The study did not take into account the coronavirus vaccine manufactured by Johnson & Johnson, but Dr. Ellebedy said he believed the immune response was less permanent than that of mRNA vaccines.

Dr. Ellebedy and colleagues reported last month that in people who survived Covid-19, immune cells that recognize the virus remain dormant in the bone marrow for at least eight months after infection. A study by another team showed that so-called memory B cells continue to mature and strengthen for at least a year after infection.

Based on these results, the researchers suggested that immunity in people infected with the coronavirus and later vaccinated could last for years, possibly a lifetime. However, it was unclear whether vaccination alone could have a similar long-lasting effect.

Dr. Ellebedy addressed this question by examining the source of memory cells: the lymph nodes, where immune cells train to recognize and fight the virus.

After an infection or vaccination, a specialized structure forms in the lymph nodes, the germinal center. This structure is sort of an elite school for B cells – a boot camp in which they become increasingly sophisticated and learn to recognize a multitude of viral genetic sequences.

The greater the range and the longer these cells have to practice, the more likely they are to thwart any virus variants that may appear.

“Everyone is always focused on developing the virus – this shows that the B cells are doing the same,” said Marion Pepper, an immunologist at the University of Washington in Seattle. “And it will protect against the continued development of the virus, which is really encouraging.”

After an infection with the coronavirus, the germinal center forms in the lungs. But after the vaccination, the cells are formed in the lymph nodes in the armpits that researchers can reach.

Updated

July 2, 2021, 5:06 p.m. ET

Dr. Ellebedy and colleagues recruited 41 people – including eight with a history of infection with the virus – who were immunized with two doses of the Pfizer BioNTech vaccine. The team collected lymph node samples from 14 of these people three, four, five, seven and 15 weeks after the first dose.

This meticulous work makes this a “heroic study,” said Akiko Iwasaki, an immunologist at Yale. “This kind of careful time history analysis in humans is very difficult.”

Dr. Ellebedy found that 15 weeks after the first dose of the vaccine, the germinal center was still highly active in all 14 participants and that the number of memory cells that recognized the coronavirus had not decreased.

“The fact that the reactions lasted almost four months after the vaccination – that’s a very, very good sign,” said Dr. Ellebedy. Sprouting centers typically peak one to two weeks after vaccination and then decrease.

“Usually there isn’t much left after four to six weeks,” said Deepta Bhattacharya, an immunologist at the University of Arizona. But germinal centers that are stimulated by the mRNA vaccines “still go in, months, and most people don’t go back much”.

Dr. Bhattacharya noted that most of what scientists know about the persistence of germinal centers is based on animal studies. The new study shows for the first time what happens to people after vaccination.

The results suggest that the vast majority of those vaccinated will be protected in the long term – at least against the existing coronavirus variants. But older adults, people with weak immune systems, and those taking drugs that suppress immunity may need boosters; People who survived Covid-19 and were later vaccinated may not need it at all.

It is difficult to predict exactly how long protection against mRNA vaccines will last. In the absence of variants that bypass immunity, immunity could theoretically last a lifetime, experts said. But the virus is clearly evolving.

“Anything that would actually require a refresher would be variant-based, not immunity waning,” said Dr. Bhattacharya. “I just don’t see it.”

People who have been infected with the coronavirus and then immunized see a sharp spike in their antibody levels, likely because their memory B cells – which produce antibodies – had many months to develop before vaccination.

The good news: a booster vaccine is likely to have the same effect on people who have been vaccinated as a previous infection, said Dr. Ellebedy. “If you give them another chance to get involved, they’ll have a massive response,” he said, referring to memory B cells.

In terms of boosting the immune system, vaccination is “probably better” than recovering from the actual infection, he said. Other studies have shown that the repertoire of memory B cells produced after vaccination is more diverse than that produced by infection, suggesting that the vaccines protect against variants better than natural immunity alone.

Dr. Ellebedy said the results also suggest that these signs of sustained immune response could be caused by mRNA vaccines alone, as opposed to those made by more traditional means like Johnson & Johnson’s.

But that’s an unfair comparison because the Johnson & Johnson vaccine is given as a single dose, said Dr. Iwasaki: “If the J&J had a booster, they might get the same kind of reaction.”

Categories
Health

CRISPR gene enhancing may attain sufferers ‘very quickly’: Intellia CEO

Following a breakthrough trial where gene-editing technology CRISPR completed its first systematic delivery as medicine to a human body, Intellia Therapeutics CEO John Leonard said he hopes the gene therapy could be made available to patients “very, very soon.”

“These approaches are subjected to the standard sorts of clinical trials that any drug or gene therapy would be studied under, so we’re in the earlier stages of that,” Leonard said on CNBC’s “Closing Bell” on Thursday afternoon.

He added that over the next few years, the company expect the medical technology to be subjected to standard reviews, “but our hope is that this will be available to patients very, very soon.”

CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.

The latest development, the result of a trial between Intellia and biotech company Regeneron, treated a rare disease after being given as an IV infusion. Previously, other applications of the CRISPR technology had been limited to ex vivo therapy, or where cells are removed from the body for genetic manipulation in a laboratory and then reintroduced to the body.

“What’s particularly exciting about that is we were able to completely inactivate that gene and see that in the clinical effects of the patient, so a major advance in the gene editing space,” Leonard said.

Heart, diabetes and broad disease implications

CRISPR has broad applications, and Leonard said there is a lot of work being done to target some of the most common diseases and causes of death, such as heart disease and diabetes.

“The challenge is getting into those particular genes that cause disease, so we started in the liver, which is an area where there are many problems with disease-causing genes, and it’s been shown that we can reach that very, very successfully,” Leonard said. “There’s other tissues after that that we’re pursuing, especially the bone marrow, where a long list of blood-borne-type diseases can be addressed.”

A key for CRISPR is targeting diseases that are monogenic, or caused by one particular gene, allowing this type of gene-editing therapy to be successful, Leonard said. Other diseases that are polygenic, such a cancers or autoimmune diseases, will be “more difficult to tackle,” he added.

A researcher watches the CRISPR/Cas9 process through a stereomicroscope at the Max-Delbrueck-Centre for Molecular Medicine.

picture alliance | picture alliance | Getty Images

The new treatment is still in the early stages and it has not been priced yet, but as it develops, Leonard said he believes it will be “very valuable for patients and probably resource sparing for the health care system overall.”

“It really comes down to the some of the advantages with single application where literally it’s a one-and-done therapy,” Leonard said. “We expect over time this will be generally very, very favorable in the economics of this entire field.”

Jennifer Doudna, who was awarded the 2020 Nobel Prize in chemistry for her work on CRISPR gene editing and is the co-founder of Intellia, recently told the CNBC Evolve Global Summit that cost is a significant challenge, and in the case of sickle cell anemia, where CRISPR has had early success, treatment can still be $2 million.

“That is clearly not a price point that will make this available to most people that can benefit from it,” she said. Innovations in delivery of CRISPR may help lower cost, but Doudna also said that the medical field needs to figure out how to “scale the molecule production so that we reduce costs.”

She told CNBC the evolution of the technology from the publication of her early work to clinical trials showing it to be effective in treating diseases in less than 10 years represents, “One of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”

“It’s largely because the technology comes at a moment when there’s enormous demand for genome editing, as well as a lot of knowledge about genomes,” Doudna said.

Categories
Health

Zoo Animals Are Getting Experimental Coronavirus Vaccines

The Oakland Zoo in California started this week with bears, mountain lions, tigers and ferrets, the first of about 100 animals to receive an experimental vaccine against the coronavirus this summer.

Zoetis, a veterinary drug company, is donating 11,000 doses of the vaccine to approximately 70 zoos, sanctuaries, universities, and other wildlife sanctuaries in 27 states, and Oakland Zoo is one of the first to benefit. The vaccine is only intended for animals, is going through a different approval process than for humans and cannot be used to protect humans.

“It means a lot more safety for our beautiful animals,” said Dr. Alex Herman, vice president of veterinary services at Oakland Zoo. “Our very first animals to be vaccinated in the zoo were two of our beautiful and older tigers.”

There were no cases of animals infected with SARS-CoV-2, the virus that causes Covid in humans, at the Oakland Zoo. But the zoo has taken extraordinary precautions, said Dr. Herman, by asking the zookeepers to keep a safe distance from the animals and to wear protective equipment.

However, big cats and other endangered animals such as gorillas have been infected in zoos in the United States and elsewhere. The San Diego Zoo vaccinated monkeys in February with the Zoetis vaccine, which was first tested on minks.

The New Jersey-based company made the same experimental vaccine available to Oregon mink farmers after the state ruled this spring that all mink it farms must be vaccinated. The US Department of Agriculture approved the vaccine for experimental use “on a case-by-case basis,” said Christina Lood, senior communications director at Zoetis.

The vaccine donation is the latest development in the patchwork response to animals infected with the virus.

Since the beginning of the pandemic, pet owners, zookeepers, fur keepers and scientists all have had their own specific concerns about animal infections. Pet owners have been concerned about the health of beloved cats and dogs, while epidemiologists and public health officials have warned that some species – domestic or wild – could become reservoirs where the virus can live and mutate, even if the world tries to fight it In people.

The U.S. Department of Agriculture has not considered vaccine candidates for cats or dogs, and veterinarians have consistently found that there is no evidence that pets can transmit the virus to humans. However, the virus was transmitted to humans from the cultured mink.

Updated

July 2, 2021, 5:06 p.m. ET

However, scientists continue to determine that both cats and dogs get the virus from their owners. Cats are more susceptible, and although most have mild symptoms, several studies have reported cats with severe symptoms. A cat in the UK had to be euthanized.

Dr. Dorothee Bienzle, a veterinarian and immunologist at the University of Guelph in Ontario, who recently completed a study of cats and dogs in households with people with Covid, found several cases of cats with severe symptoms. However, she said that all other diseases should have been ruled out in order to definitively assign the symptoms to the coronavirus; this was not possible in their study, which depended on blood samples and descriptions of symptoms from the owners.

Dr. Karen Terio, a veterinarian and pathologist at the University of Illinois Veterinary School at Urbana-Champaign, repeated that sentiment, saying, “I have heard of cats with severe clinical symptoms but have not seen any cases where they could confirm the signs were on SARS-CoV-2. “

At the latest online meeting of the European Congress of Clinical Microbiology & Infectious Diseases, Dr. Bienzle preliminary research that she and her colleagues had conducted.

They first tested cats and dogs in households where people tested positive for the coronavirus. “We focused on a likely positive population group,” said Dr. Bienzle.

They found that, as expected, more cats than dogs tested positive, 67 percent versus 43 percent. In cats, too, the time they spent with their owners, especially sleeping in the same bed, increased the risk of infection. This was not the case with dogs.

The researchers then tested cats that were taken to animal shelters and cats that were taken to inexpensive clinics for neutering. These cats, not known to have lived with infected humans, had a remarkably lower rate of infection, 9 percent in cats in shelters and only 3 percent in cats brought to clinics.

Dr. Bienzle said the advice to pet owners has remained consistent throughout the pandemic. If you have Covid, isolate yourself from your pets as you would from a human. Neither the United States nor Canada endorses vaccination of pets. Dr. Bienzle said that human transmission to the animals could be prevented through social distancing and masks.

Researchers in protected areas and those who work with endangered species like bats have taken stricter measures to keep the animals safe from infection.

For zoos, the question is not whether to vaccinate, but how to approach the patient if it is a tiger. “With a lot of positive reinforcement,” said Dr. Herman. The zoo trains its animals by giving them rewards so that they can voluntarily be stung. It’s pretty much the same idea as getting a lollipop after a shot, though animals are more willing to volunteer than humans.

“The tiger is leaning against the fence,” said Dr. Herman. “The thousand-pound grizzly bear is leaning against the fence.”

Good tiger. Good bear.

Categories
Health

Covid danger low for many People to assemble over Fourth of July weekend, Gottlieb says

Dr. Scott Gottlieb told CNBC on Friday that most Americans should be comfortable gathering together safely on Independence Day weekend, citing high Covid vaccination rates and low virus infection rates in many parts of the country.

However, the former Commissioner of the Food and Drug Administration said there are certain places where people should be more careful.

“There is a very low prevalence across the country. You have to be based on where you are, ”said Gottlieb in“ Squawk Box ”. He noted that in his home state of Connecticut, new daily cases are small, “so it’s a pretty safe environment to get together right now.”

“In some parts of the country where prevalence is increasing – Missouri, parts of Nevada, Arkansas, Oklahoma – I think people should exercise more caution,” added Gottlieb, who sits on the board of directors at Covid vaccine maker Pfizer.

Gottlieb’s comments come before the July 4th weekend as U.S. health officials closely monitor the Covid Delta variant, which is believed to be significantly more transmissible than dominant strains earlier in the pandemic.

Coronavirus cases in the country are dramatically lower than their peak in January when the country recorded over 300,000 new infections in a single day, but has been trending upward in recent days, according to a CNBC analysis of Johns Hopkins University data.

The US recorded an average of about 12,700 new Covid cases per day in the past week, the analysis showed. That’s 9% more than a week ago.

“We don’t want to worry people, but we’re following these numbers very, very carefully,” said CDC Director Dr. Rochelle Walensky NBC News after a White House briefing Thursday.

The number of deaths continues to decline. The seven-day average of new Covid deaths is 249, according to CNBC analysis, a 19% decrease from a week earlier.

“There are kind of isolated parts of the country where the number of infections is increasing. The rest of the country looks very good,” said Gottlieb. “I think what you are seeing is a decoupling between places with high vaccination rates and places with low vaccination rates. You also see, frankly, a decoupling between the cases and extreme death and the disease that caused this virus.”

In countries with high vaccination rates, but also increasing cases due to the Delta variant, such as Great Britain and Israel, “hospitals and deaths are no longer increasing” as they did earlier in the global health crisis, said Gottlieb.

“For a while, we thought it was just the delayed effect where hospital admissions weren’t seen until three or four weeks after the number of cases rose, just like deaths,” said Gottlieb, who headed the FDA from 2017 to 2017 2019 in the Trump administration.

“But at this point we have enough trending to suggest that now you will only see decoupling and not see the extreme results of the virus in parts of the world where vaccination rates are high. and that includes the United States. “

Because of this, Gottlieb said, it’s important to make sure more Americans get a coronavirus vaccine, which will reduce both the spread of the virus and the risk of getting seriously ill or dying from the disease.

Nearly 156 million Americans are fully vaccinated, according to the CDC. Just over 181 million people have received at least one dose; Pfizer and Moderna vaccines require two vaccines while Johnson & Johnson’s are a single dose.

However, there are geographical gaps in vaccination coverage. CDC’s Walensky said Thursday that fewer than 30% of residents are vaccinated in about 1,000 U.S. counties, most of which are in the Southeast and Midwest.

Overall, 47% of the US population is fully vaccinated.

“Preliminary data for the past six months suggests that 99.5% of deaths from Covid-19 in the US have occurred in unvaccinated people … the suffering and loss we see now are almost entirely preventable,” Walensky said .

Gottlieb said despite being fully vaccinated, he is still looking for ways to be cautious as the pandemic is not completely lagging behind the country.

“For example, if I am going to a restaurant and there is an opportunity to sit outside, I will eat outside. I think where you can be a kind of nervous Bayesian and lower your statistical probability of coming into contact with the virus, why not? ”Said Gottlieb. “But I wouldn’t hold back from meeting friends and family on this holiday because the virus is spreading in very small numbers in certain parts of the country.”

Categories
Health

Is Biden Declaring ‘Independence From the Coronavirus’ Too Quickly?

“There is so much toxic politics around Covid that it’s constraining sensible action,” he said. “Obviously it makes sense to require proof of vaccination in various settings, but that has become a political lightning rod.”

Dr. Frieden and other experts said they feared that if the Delta variant continues to circulate, it will mutate in a way that leaves even the vaccinated vulnerable. That already seems to be happening elsewhere in the world; even countries like South Korea and Israel, where the virus seemed to be in check, have new clusters of disease.

“Compared to many other countries, we are in a much more secure situation,” said Dr. Jennifer Nuzzo, an epidemiologist at Johns Hopkins University. But, she added, “I really do worry that as America enjoys its freedoms, we forget about the rest of the world, and that could come back to bite us.”

When Mr. Biden announced his July 4 vaccination goal in early May, he said meeting it would demonstrate that the United States had taken “a serious step toward a return to normal.” For many people, that seems to be the case. The president said then that Americans would be able to gather in backyards for small Independence Day barbecues; his gathering of 1,000 guests is partly aimed at showing the country that his administration has exceeded expectations even if vaccinations have stalled.

While Mr. Biden has repeatedly spoken of “independence from the virus,” Dr. Arthur L. Caplan, the director of NYU Langone Medical Center’s medical ethics division, said the president should be careful about the language he uses.

“Before I went out and had my fireworks and sipped piña coladas on the White House veranda, I would say, ‘I’ve got to make clear, as president, we have major challenges unresolved,’” Dr. Caplan said. “I would say, ‘We’re doing well at halftime.’”

Dr. Anthony S. Fauci, the president’s top medical adviser for the pandemic, said there was nothing contradictory about the administration’s message.

Categories
Health

5 issues to know earlier than the inventory market opens Friday, July 2

Here are the top news, trends, and analysis investors need to start their trading day:

1. Stock futures rise according to the June job report

Traders work on the floor of the New York Stock Exchange on November 4th. 2020.

NYSE

US stock futures rose Friday morning following the release of the better-than-expected June job report. All major street indices closed on Green Thursday as Wall Street got off to a positive start into the second half of 2021 after a strong first half. The S&P 500 rose 0.5% to 4,319.94, its sixth record high in a row. The Dow Jones Industrial Average added 131 points, ending the session at 34,633.53. The 30-person Dow has risen three sessions in a row and is at its highest level since June 4th. The tech-heavy Nasdaq rose 0.13% to 14,522.38 on Thursday. The key averages are all positive for the week and at the level of their second consecutive weekly gain.

2. The US created 850,000 jobs in June

A company is advertising an Aid sign on April 9, 2021 in Pawtucket, Rhode Island.

Spencer Platt | Getty Images

The number of employees outside the agricultural sector rose by 850,000 in June, the Ministry of Labor said on Friday. The number is better than the 706,000 jobs economists were expecting, Dow Jones estimates. However, the unemployment rate rose to 5.9%, while the projections forecast a decline to 5.6%. Average hourly wages rose 0.33% in June and 3.6% year-on-year; both numbers correspond to the estimates. The Department of Labor’s April and May employment reports fell short of Wall Street’s expectations as companies across all industries said they were having difficulty filling vacancies.

3. Robinhood applies for the highly anticipated IPO

Pavlo Gonchar | LightRakete | Getty Images

In its highly anticipated IPO on Thursday, Robinhood Markets announced that it has 18 million retail clients and more than $ 80 billion in client assets. The free stock trading pioneer said it was profitable in 2020, posting net income of $ 7.45 million on net sales of $ 959 million as the number of accounts funded more than doubled that year. In 2019, Robinhood lost $ 107 million on net sales of $ 278 million.

Robinhood ended the first three months of this year in a loss of $ 1.4 billion, related to the emergency funding it closed during the peak of the Reddit-fueled GameStop madness in January. Revenue for the quarter rose 309% to $ 522 million, compared to $ 128 million in the first quarter of 2020. Approximately 38% of Robinhood’s revenue comes from options trading accounts. Stocks make up 25% of sales, while crypto makes up 17%.

Founded in 2013, the company plans to raise $ 100 million when it goes public. It intends to list on the Nasdaq and trade under the ticker “HOOD”.

4. Virgin Galactic plans to launch Richard Branson on July 11th

Sir Richard Branson stands on the trading floor of the New York Stock Exchange (NYSE) in front of the trading of Virgin Galactic (SPCE) in New York, USA, 28 October 2019.

Richard Branson Virgin Galactic IPO NYSE

Space tourism company Virgin Galactic has scheduled its next test flight for July 11th and company founder Sir Richard Branson intends to be on board. The timing is particularly noteworthy as British billionaire Jeff Bezos plans to launch into space. The Amazon founder and richest person in the world is due to launch his own company Blue Origin on July 20th. Virgin Galactic’s shares rose about 30% in pre-trading hours to about $ 56 each. The planned launch will be Virgin Galactic’s fourth test space flight to date. Branson founded Virgin Galactic in 2004 and the company began trading on the New York Stock Exchange in October 2019.

5. Toyota outperforms GM in the US for the first time in a quarter

A Toyota Tundra pickup truck is seen at a dealership in San Jose, California.

Yichuan Cao | NurPhoto | Getty Images

Toyota Motor sold more vehicles in the US than General Motors in the second quarter. This is the first time the Japanese automaker has done this in a three-month period. On Thursday, Toyota said it had sold 688,813 vehicles in America from April to June, almost ousting GM’s 688,236 vehicles. Toyota’s results exceeded analysts’ expectations; GMs fell short. Toyota may become the best-selling automaker in the US, depending on where Ford’s results come in. GM’s Crosstown rival reported the number on Friday morning, and analysts are forecasting US sales of 645,000 vehicles in the second quarter. The last time GM wasn’t America’s best-selling automaker for a quarter was in the third quarter of 1998 when Ford oversold them, according to Edmunds.

The automotive industry has coped with semiconductor shortages and messed up production schedules at a time when consumer demand for new vehicles was strong. Toyota and other Japanese automakers have weathered the chip crisis better than their US rivals so far.

Correction: The Nasdaq closed at 14.522.38 on Thursday. In a previous version the number was incorrectly specified.

– Follow the whole market like a pro on CNBC Pro. Get the latest on the pandemic with coronavirus coverage from CNBC.

Categories
Health

Coaching the Subsequent Era of Indigenous Information Scientists

“Native DNA is so sought after that people are looking for proxy data, and one of the big proxy data is the microbiome,” said Yracheta. “If you are a Native, you need to consider all of these variables if you are to protect your people and culture.”

In a presentation at the conference, Joslynn Lee, a member of the Navajo, Laguna Pueblo and Acoma Pueblo Nations and a biochemist at Fort Lewis College in Durango, Colorado, shared her experience of tracking changes in microbial communities in rivers that drained mine wastewater Silverton, Colorado, discontinued. Dr. Lee also provided practical tips on planning a microbial analysis, from taking a sample to processing it.

Rebecca Pollet, a biochemist and member of the Cherokee Nation, took a data science career panel on how many mainstream pharmaceuticals were developed based on traditional knowledge and plant medicine of the indigenous people. The anti-malarial drug quinine, for example, was developed from the bark of a species of cinchona that the Quechua people used as medicine in the past. Dr. Pollet, who studies the effects of drugs and traditional foods on the gut microbiome, asked, “How do we honor this traditional knowledge and compensate for what has been covered up?”

One participant, Lakota Elder Les Ducheneaux, added that he believed that medicine derived from traditional knowledge mistakenly removed the prayers and rituals that traditionally accompanied treatment, making the medicine less effective. “You have to constantly balance the scientific part of medicine with the cultural and spiritual part of your job,” he said.

During the IndigiData conference, attendees also discussed ways to manage their own data to serve their communities.

Mason Grimshaw, data scientist and board member of Indigenous in AI, spoke about his research on language data at the International Wakashan AI Consortium. The consortium, led by engineer Michael Running Wolf, is developing automatic speech recognition AI for Wakashan languages, a family of endangered languages ​​spoken by multiple First Nations communities. The researchers believe that automatic speech recognition models can preserve the fluency of the Wakashan languages ​​and revive their use by future generations.

Categories
Health

Israel, UAE, Bahrain vaccination and an infection traits

Two women in face masks walk along a shopping area on April 19, 2021 in Dubai, United Arab Emirates.

Francois Nel | Getty Images News | Getty Images

Vaccination campaigns in several Middle East nations raced ahead of the rest of the world at the beginning of 2021.

Israel, the United Arab Emirates and Bahrain topped the list when it came to doses administered per 100 people at the start of the year.

Six months later, all three are still among the top 10 most vaccinated countries — but charts show their Covid infection trends have varied greatly.

As of June 29, 57.8% of Bahrain’s population were fully vaccinated and 59.7% of Israel’s residents received both doses of the Covid vaccine, according to Our World in Data. The UAE’s data on fully vaccinated individuals was last updated on April 20, when the figure stood at 38.8%.

Israel

Israel’s new daily cases plummeted as its vaccination program ploughed on, and data showed that infections remained largely in the low double-digits for more than a month since the end of April. That was so until a resurgence emerged in late June.

Caseloads are a fraction of previous peaks, but have risen rapidly in recent days.

The highly contagious delta variant is responsible for about half the new cases, according to Nadav Davidovitch, chair of the Israeli Association of Public Health Physicians.

Still, simulations predict that even with “widespread transmission,” there will only be several hundred severe cases, he told CNBC via video call. “Not like it used to be in the third wave,” he added, referring to the spike that began late last year.

UAE

The United Arab Emirates ranks number one in terms of total doses administered per 100 people, according to Our World in Data. But new infections in the country have stubbornly hovered around 2,000 per day.

Cases have fallen from the record highs reported in January, and temporarily dipped to the mid-1,000 level in May, but have otherwise mostly stayed around the same region.

Still, the cases now remain higher than the average daily cases of about 1,200 reported in the fourth quarter of 2020.

The UAE’s National Emergency Crisis and Disaster Management Authority in May announced that it would be offering a third dose of China’s Sinopharm vaccine. It came amid questions over the efficacy of the vaccine as there were reports of infections in individuals who had received two shots.

The country later said those inoculated with Sinopharm’s vaccine can receive the Pfizer-BioNTech shot as a booster, Reuters reported.

Bahrain

Infections in Bahrain hit record highs in late May even though vaccinations were well underway in the country.

According to Our World in Data, the kingdom reported 3,273 new cases on May 29.

At that point, more than 911,000 people in Bahrain had already received at least one dose of a Covid vaccine. It has a population of around 1.76 million people.

New daily cases have since fallen to the hundreds.

Bahrain is also offering third doses of Sinopharm’s vaccine. Booster shots of the Pfizer-BioNTech vaccine are available to more vulnerable groups such as those above the age of 50, three months after they receive a second dose of Sinopharm.

Deaths attributed to Covid

Infections are not the only indicator of a country’s coronavirus situation, and vaccinations are not the only factor at play.

Besides inoculation, a country’s demographics and Covid restrictions also play a part in the severity of illness and how quickly the virus spreads.

Deaths in Israel and the UAE have fallen and stayed low, while daily new Covid-related deaths per million in Bahrain went as high as 17 in June.

Are Covid spikes a concern?

The outbreaks in the Middle East countries are not worrying, said Paul Tambyah, president of the Asia Pacific Society of Clinical Microbiology and Infection.

“I do not think that we should be too concerned,” he told CNBC in an email. “The majority, or at least a significant proportion of cases have reportedly been in those who have not been vaccinated.”

“The main concern is that it does not look like we can get away without vaccinating a very significant proportion of the population,” he said.

I think that as long as the virus is circulating globally and borders remain open, there will be occasional outbreaks of the virus even in highly vaccinated populations.

Paul Tambyah

Asia Pacific Society of Clinical Microbiology and Infection

Virus clusters expected

High vaccination rates will not rule out clusters of cases in future, medical experts said.

“I think that as long as the virus is circulating globally and borders remain open, there will be occasional outbreaks of the virus even in highly vaccinated populations,” said Tambyah.

Davidovitch said “localized outbreaks” among children who are not vaccinated will probably continue.

He said it’s “hard to tell” if a reliance on Chinese vaccines — as seen in the UAE and Bahrain — may be linked to dramatic spikes in Covid cases.

Tambyah noted that Israel, which has used mainly Pfizer vaccines, is seeing a resurgence in cases as well.

He said there are no scientific publications comparing traditional vaccines developed by China against vaccines that rely on messenger RNA technology, which instructs the body to produce a harmless piece of the virus that helps trigger an immune response.

“I think that, unfortunately, higher vaccination rates are required,” Tambyah said.

Categories
Health

Johnson & Johnson Vaccine Protects In opposition to Delta Variant, Firm Experiences

Johnson & Johnson’s coronavirus vaccine is still effective eight months after being vaccinated against the highly contagious Delta variant, the company reported Thursday – a result that should reassure the 11 million Americans who received the vaccination.

The vaccine showed a slight decrease in effectiveness against the variant compared to its effectiveness against the original virus, the company said. But the vaccine was more effective against the Delta variant than the beta variant, which was first identified in South Africa – the pattern was also seen with mRNA vaccines.

Antibodies stimulated by the vaccine get stronger over time, researchers also reported.

The results were described in a press release, and the company announced that both studies were submitted for online publication on Thursday. One of these studies was accepted for publication in a scientific journal. Both studies are small, and the researchers said they published the results early because of the great public interest.

“The coverage of the variants will be better than expected,” said Dr. Dan Barouch, a virologist at Beth Israel Deaconess Medical Center in Boston. “There was a lot of misinformation out there so we decided we had to get this public right away.”

The intense discourse about Delta’s threat has made even immunized people worry about whether they are protected. The variant first identified in India is much more transmissible than previous versions of the virus, and its global spread has resulted in new health restrictions from Ireland to Malaysia.

In the USA, the variant now accounts for every fourth new infection. Public health officials said the vaccines approved in the United States will work against all existing variants, but the data is primarily based on studies of the mRNA vaccines from Pfizer-BioNTech and Moderna.

That made some people who received the Johnson & Johnson vaccine ask, What about us?

The frustration built before the Delta variant appeared. For example, the guidelines from the Centers for Disease Control and Prevention that vaccinated people could do without masks in many indoor situations were mainly based on data for mRNA vaccines. And reports of an accumulation of infections among players on the Yankees baseball team that the J. & J. Shot did nothing to allay fears that the vaccine might be inferior to others.

Martha Young, 63, of Mountain View, California received the J. & J. shot on April 9th. It wasn’t their first choice, but it was offered. But since then she has said, “I’m very, very frustrated with the lack of information.”

She added, referring to the J. & J. “I felt like I didn’t count, like I was statistically insignificant because so few of us stand a chance that we don’t have to worry about us.”

Some people familiar with the J. & J. Vaccine complained that they felt cheated by experts who said the vaccines were all equally good. “I was surprised to see others make that claim,” said Natalie Dean, biostatistician at the University of Florida. “I did not like it. People don’t want to feel misled. “

However, other experts said the clinical trials should have shown that the J. & J. Vaccine was lower than that of the mRNA vaccines. “Of course, 72 percent is less than 95 or 94 percent,” says Florian Krammer, an immunologist at the Icahn School of Medicine on Mount Sinai in New York.

Part of the difficulty with comparing the vaccines is that they were all tested individually and with different measures of success. The Pfizer-BioNTech and Moderna studies were designed to capture symptomatic infections, while the J. & J. Study looked at the prevention of moderate to severe infections by the vaccine.

Still, it’s clear that all vaccines keep people out of the intensive care unit and morgue far more effectively than scientists could hope for, said Danny Altmann, an immunologist at Imperial College London.

Updated

July 1, 2021, 10:13 p.m. ET

“It’s like arguing whether you want a Ferrari or a Porsche that goes 250 or 180 mph on a road that is only allowed to drive 30 miles an hour,” he said.

However, there are differences: The J. & J. The vaccine can allow more so-called breakthrough infections – which occur in people who are fully vaccinated – with mild to no symptoms than the mRNA vaccines.

People with asymptomatic infections are very unlikely to spread the virus, but their diagnosis can become a problem when they’re caught by routine tests – as was the case with the Yankees cluster – and they have to go into quarantine, said John Moore, one Virologist at Weill Cornell Medicine in New York.

Information on the effectiveness of the J. & J. The vaccine was slow to get to market because it was launched later and its use was suspended due to concerns about infrequent blood clots. Many medical centers and hospitals offered staff the mRNA vaccines early on and were able to conduct studies to evaluate these vaccines.

But blood samples from people who were tested with the J. & J. Vaccines are a comparatively rare commodity, said Dr. Krammer. “It’s not that nobody cares, or we’re hiding something because the vaccine isn’t good,” he said. “It’s more of an access problem.”

In the absence of data, some experts had suggested that the J. & J. Vaccination against the Delta variant probably performed about as well as the AstraZeneca vaccine, which is widely used in Europe. But this vaccine is given in two doses compared to J. & J’s single dose.

“The thing that I do at J. & J. is that their technology platform is essentially very, very similar – almost indistinguishable from AstraZeneca, ”said Dr. Altmann. “Should it really be a two-dose vaccine like everything else?”

The single dose offers benefits for those with limited access or who do not want two doses for other reasons. The J. & J. The vaccine also lasts longer in the refrigerator than the others and was a welcome option earlier in the pandemic when vaccines were scarce.

But after the advent of variants like Beta and Delta, which seem to bypass the immune system in part, the discussion about boosters for J. & J. Receiver intensified. One dose of the AstraZeneca vaccine is much less effective against variants than two doses, and experts feared that J. & J. Shot could be similar.

The new study addressed some of these concerns.

While blood antibody levels produced after immunization with Pfizer or Moderna decrease after an initial increase, antibodies – and immune cells – are released by the J. & J. Vaccine remains at a high level. (Other studies have shown that immune responses generated by mRNA vaccines are likely to last for years, too.)

A lack of information about the J. & J. Vaccine had led many people to speculate that it might need to be supplemented with a dose of an mRNA vaccine. But at least for now, people who have the J. & J. Vaccine shouldn’t need a booster shot, nor can they legally get one, “unless they’re playing the system, unless they pretend they’re vaccine naïve and get an mRNA vaccine and are essentially lying,” said Dr . Moore, “and I certainly … don’t recommend people do that.”

Categories
Health

The White Home is taking proper method in preventing the Covid-19 delta variant, Gottlieb says

The Biden government is taking the right approach in tackling the highly contagious Covid-19 Delta variant by deploying response teams to vulnerable communities, said Dr. Scott Gottlieb on Thursday.

“I think the government is doing the right thing when it comes to changing its strategy,” Gottlieb, the former FDA chief under former President Donald Trump, told CNBC’s “The News with Shepard Smith” about the grassroots approach new government.

Gottlieb explained that the targeted response can help teams focus on vaccinating the communities prone to Covid and the Delta variant.

“Right now we need to move to a grassroots strategy and try to put resources into local communities so that local groups can encourage people to get vaccinated, put the vaccines in the hands of doctors, and find ways to get more vaccines to get into the hands of small providers who can encourage their patients to vaccinate, “said Gottlieb.

The Delta variant is driving a sharp spike in new Covid cases across the country and currently accounts for about 25% of the new cases sequenced in the US. Officials believe it will become the dominant strain in the country, dwarfing the currently dominant alpha variant.

Rochelle Walensky, director of the Centers for Disease Control and Prevention, attributed the increase in part to delayed vaccination rates. The CDC director added that about a third of all counties across the country have so far vaccinated less than 30% of their population. She said most of them are in the South and Midwest.

Disclosure: Scott Gottlieb is a CNBC employee and a member of the board of directors of Pfizer, genetic testing startup Tempus, health technology company Aetion Inc., and biotechnology company Illumina.